Search Results
Your search for A matches 32969 pages
Showing 6551 - 6600
Timothy A. Yap, MBBS, PhD, on Developing Novel Therapeutic Strategies to Target DNA Damage Response in the Clinic
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses how research is building on the success of first-generation PARP inhibitors in the clinic and the potential of novel potent PARP1-selective inhibitors, which may lead to improved patient outcomes. Given...
Timothy A. Yap, MBBS, PhD, on Advanced Solid Tumors With DNA Damage Response Defects: Early Data on Elimusertib
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from a phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response defects....
Gulam A. Manji, MD, PhD, on Gastric and Gastroesophageal Junction Adenocarcinomas: New Data on Pembrolizumab Plus Capecitabine and Oxaliplatin
Gulam A. Manji, MD, PhD, of Columbia University Medical Center, discusses phase II results on perioperative combination chemotherapy and pembrolizumab in patients with resectable gastric cancer. The combination appeared to result in many complete pathologic responses (Abstract CT009).
Marcia R. Cruz-Correa, MD, PhD, on a Vision for the Future of Cancer Research and Treatment
Marcia R. Cruz-Correa, MD, PhD, of the University of Puerto Rico Comprehensive Cancer Center, discusses a way to possibly transform cancer outcomes by teaming up basic scientists, clinical researchers, and community advocates to work together, decode the complexity of cancer, and find points at...
Expert Point of View: Aditya Bardia, MD, MPH
Aditya Bardia, MD, MPH, Director of Breast Cancer Research and Attending Physician at Massachusetts General Hospital, and Associate Professor at Harvard Medical School, commented on this study on recurrence of ductal carcinoma in situ (DCIS). “This is an interesting study that evaluated whether...
Some Recurrences of Ductal Carcinoma In Situ May Be Genetically Distinct From the Primary Tumor, Study Reports
Contrary to what has been assumed, all recurrences of ductal carcinoma in situ (DCIS) are not genetically the same, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 Almost 20% of ipsilateral recurrences found in the study were genetically...
Two Studies Examine Use of Proton-Beam Therapy in the United States
Two new, large studies led by researchers at the American Cancer Society showed an increase in the use of proton-beam therapy for patients with cancer in the United States during the past decade. However, Black patients were less likely to receive proton-beam therapy than White patients, and the...
New Study Examining Women’s Breast Density Knowledge Suggests Opportunities for Improvement
Breast density is one factor in assessing a person’s risk of developing breast cancer. Existing breast density notification laws have increased awareness among patients and providers, but clinical records had not been incorporated in studies to confirm the accuracy of personal breast density...
Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer
In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in patients with platinum-resistant ovarian cancer. Delta-like ligand 4 is a...
Assessment of Cancer Risk Profile for Germline BRCA1 and BRCA2 Pathogenic Variants in Patients With Common Cancers
In a Japanese case-control study reported in JAMA Oncology, Momozawa et al found that germline BRCA1/2 pathogenic variants were associated with an increased risk of biliary tract, esophageal, and gastric cancers, in addition to an increased risk of cancers that have well-established associations...
Narsoplimab for Hematopoietic Stem Cell Transplantation–Associated Thrombotic Microangiopathy
In a pivotal phase II trial reported in the Journal of Clinical Oncology, Samer K. Khaled, MD, and colleagues found that narsoplimab, an inhibitor of mannan-binding lectin-associated serine protease-2, showed efficacy in the treatment of adult patients with hematopoietic stem cell...
First-Line Therapy for BRCA2-Mutated Metastatic Castration-Resistant Prostate Cancer
This is Part 3 of Updates in Prostate Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Celestia (Tia) Higano, Julie Graff, and Neal Shore discuss the first-line therapy for BRCA2-mutated metastatic castration-resistant...
Doublet or Triplet Androgen-Deprivation Therapy Options for Metastatic Prostate Cancer
This is Part 2 of Updates in Prostate Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Celestia (Tia) Higano, Julie Graff, and Neal Shore discuss doublet and triplet androgen-deprivation therapy options for metastatic...
Elderly Patient With Metastatic Hormone-Sensitive Prostate Cancer
This is Part 1 of Updates in Prostate Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. �In this video, Drs. Celestia (Tia) Higano, Julie Graff, and Neal Shore discuss the management of metastatic hormone-sensitive prostate cancer in elderly...
Study Examines Rates of Psychiatric Disorders and Self-Harm Among Patients Diagnosed Across 26 Cancer Types
The risk of self-harm after incident psychiatric disorder diagnosis in patients with 26 cancer types and the risk of unnatural deaths after self-harm were examined in 459,542 individuals in a study published by Chang et al in Nature Medicine. Patients with cancer may experience substantial...
Addition of High-Dose Treosulfan and Melphalan to Consolidation in High-Risk Ewing Sarcoma
In a phase III trial (Ewing 2008R3) reported in the Journal of Clinical Oncology, Koch et al found that the addition of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells to consolidation did not improve event-free survival vs ...
AI May Assist Physicians in Better Assessing the Effectiveness of Bladder Cancer Treatment
In a small multi-institutional study, an artificial intelligence (AI)-based system improved providers’ assessments of whether patients with bladder cancer had complete response to chemotherapy before a radical cystectomy. These findings were published by Sun et al in Tomography. Yet the researchers ...
High-Dose Radiotherapy With Short- vs Long-Term Androgen Deprivation in Localized Prostate Cancer
As reported in The Lancet Oncology by Zapatero et al, 10-year results of the Spanish phase III DART 01/05 trial did not support the 5-year findings of significantly improved biochemical disease–free, metastasis-free, and overall survival with long-term vs short-term androgen deprivation plus...
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Carcinoma
In an interim analysis of a Chinese phase III trial (FZOCUS-2) reported in the Journal of Clinical Oncology, Li et al found that maintenance treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor fuzuloparib significantly prolonged progression-free survival vs placebo in patients with...
Maternal Malignancies May Be Identified Through Noninvasive Prenatal Test Results
In a Dutch study reported in the Journal of Clinical Oncology, Heesterbeek et al found that results of noninvasive prenatal testing for fetal aneuploidy screening using cell-free DNA derived from maternal plasma raised suspicion of maternal malignancy in a very small proportion of pregnant women....
St. Jude Receives First Group of Ukrainian Children With Cancer for Care in the United States
One month after Russia invaded Ukraine, on March 21, St. Jude Children’s Research Hospital in Memphis welcomed four Ukrainian children with cancer to be treated in the United States. Two of the children are pictured in the photos below. The four children, aged 20 months to 8 years old, traveled to...
Erratum
In the article “OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer,” which began on page 1 of the April 10 issue of The ASCO Post, a few unfortunate errors appeared, notably an incorrect P value for the overall survival comparison (after...
Tony Hunter, PhD, FAACR, Honored With 2022 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) awarded the 2022 AACR Award for Lifetime Achievement in Cancer Research to Tony Hunter, PhD, FAACR, Fellow of the AACR Academy, at its Annual Meeting in New Orleans. Dr. Hunter is the American Cancer Society Professor and Renato Dulbecco Chair at ...
From Iran to Silicon Valley, a Cancer Survivor Shares Her Story
The Iranian revolution of 1979 transformed Iran from an absolute monarchy under Shah Mohammad Pahlavi to an Islamist republic under Ayatollah Khomeini. The author of a new book called The Magic of Normal, Maky Zanganeh, PhD, was born in Iran in 1970. As a young woman, she experienced the war in her ...
Immunotherapy in B-Cell Non-Hodgkin Lymphomas: Off-the-Shelf Bispecific Antibodies
Chimeric antigen receptor (CAR) T-cell therapies are a significant advance, but they require careful patient selection, dependency on patients’ own T cells, lymphodepleting chemotherapy, possible bridging therapy, manufacturing timelines with extensive health-care coordination and cost, in...
Incidental Findings on Low-Dose CT Lung Cancer Screening in the NLST and Risk of Respiratory Disease Mortality
In an analysis of data from the National Lung Screening Trial (NLST) reported in Chest, Paul F. Pinsky, PhD, of the Division of Cancer Prevention, National Cancer Institute, and colleagues found that incidental respiratory disease–related findings on low-dose computed tomography (CT) screening...
Expert Point of View: Amandeep Salhotra, MD
Amandeep Salhotra, MD, Associate Professor of Leukemia at City of Hope, in California, said this study should form the basis for a prospective phase III study in which older patients with AML (60–75 years) should have equal chance at randomization to either arm to remove bias on the part of...
AML Study Shows Benefit of CPX-351 vs Hypomethylating Agent Plus Venetoclax in Subgroup of Older Adults
For older patients with acute myeloid leukemia (AML), front-line treatment with liposomal daunorubicin/cytarabine (CPX-351) appears to be equivalent to treatment with a hypomethylating agent plus venetoclax, according to data presented at the 2021 American Society of Hematology (ASH) Annual Meeting ...
Expert Point of View: Mikkael Sekeres, MD
Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System and a hematologist at Sylvester Comprehensive Cancer Center, applauded the IDIOME1 and IDEAL2 investigators for conducting studies. These studies, he noted, were “very difficult because of the rarity...
IDH1/2 Inhibitors Show Activity in Patients With Myelodysplastic Syndrome
The oral targeted small-molecule inhibitors of mutant IDH1 and IDH2 appear to be active in patients with myelodysplastic syndrome (MDS) harboring these mutations, according to two phase II trials by the Groupe Francophone des Myélodysplasies (GFM) and its German colleagues in the European MDS...
Association of Lifestyle and Cardiovascular Risk Factors With Hospitalization for Heart Failure Subtypes in Breast Cancer Survivors
In an analysis from the Women’s Health Initiative reported in JACC: CardioOncology, Kerryn W. Reding, PhD, MPH, RN, of the University of Washington at Seattle, and colleagues, identified the incidence of hospitalization for heart failure among postmenopausal breast cancer survivors. They reported...
Immune Checkpoint Inhibitors in Neoadjuvant or Adjuvant Therapy for Triple-Negative Breast Cancer: The Paradigm Shifts
The “holy grail” of triple-negative breast cancer therapy has been effective incorporation of drugs to improve outcomes in the early nonmetastatic setting. Although outcomes have improved with better chemotherapy drugs and schedules, triple-negative breast cancer still carries the worst prognosis...
Addition of Pembrolizumab to Chemotherapy Improves Event-Free Survival in Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, a preplanned interim analysis of the phase III KEYNOTE-522 trial has shown improved event-free survival with the addition of pembrolizumab to...
MEK Inhibition Is Now a Standard of Care in Recurrent Low-Grade Serous Ovarian Cancer: What Next?
As summarized in this issue of The ASCO Post, the highly anticipated results of the GOG 281/LOGS study, which randomly assigned patients with recurrent low-grade serous ovarian cancer to the MEK inhibitor trametinib vs standard-of-care chemotherapy or endocrine therapy, have now been reported by...
Trametinib Improves Progression-Free Survival vs Standard-of-Care Treatment in Recurrent Low-Grade Serous Ovarian Carcinoma
As reported in The Lancet by David M. Gershenson, MD, of the Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, and colleagues, the phase II/III GOG 281/LOGS trial showed that trametinib improved progression-free survival vs standard-of-care treatment...
Fixed-Dose Nivolumab and Relatlimab-rmbw for Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 18, 2022, fixed-dose nivolumab and...
New Report Offers Guidance for Standardizing Data on Sex, Gender, Sexual Orientation
On March 9, 2022, the National Academies of Sciences, Engineering, and Medicine (NASEM) issued a new report, Measuring Sex, Gender Identity, and Sexual Orientation, recommending the National Institutes of Health (NIH) implement new guidelines to standardize the collection of data on sex, gender,...
War in Ukraine: Statistics Do Not Keep Pace With Reality
Editor’s Note: The following is adapted from Dr. Hrynkiv’s presentation at the March 18 ASCO/ECO Briefing: Cancer Care During the War in Ukraine. Find resources for impacted patients and providers at asco.org/ukraine and onco-help.org. Official statistics regarding damage and losses in Ukraine are...
Philip D. Greenberg, MD, FAACR, Voted AACR President-Elect for 2022–2023
The members of the American Association for Cancer Research (AACR) have chosen Philip D. Greenberg, MD, FAACR, as the Association’s President-Elect for 2022–2023. Dr. Greenberg is the Rona Jaffe Foundation Endowed Chair and Professor and Head of the Program in Immunology, Clinical Research...
Clinical Trials Updates in the Treatment of Older Adults With Gastrointestinal Malignancies
The theme of the 2022 ASCO Gastrointestinal Cancers Symposium was “Accelerating Access to Precision Care Through Innovation.” Several studies presented at this meeting focused on older patients, who represent the majority of patients with gastrointestinal malignancies. Data reviewed at the meeting...
Norman Sharpless, MD, to Step Down as Director of the NCI
Norman E. Sharpless, MD, has announced that he has decided to step down from his position as Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), a position he has held since 2017. Dr. Sharpless will continue as NCI Director through April 29, 2022, to...
Expert Point of View: Angela DeMichele, MD, MSCE
Abstract discussant, Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania, Philadelphia, complimented the study design and conduct of the ABC trial while exploring several possible...
Phase III Trial Evaluates the Role of Aspirin in Preventing Breast Cancer Recurrence
Taking aspirin daily does not prevent breast cancer recurrence, according to research presented during the February ASCO Plenary Series Program.1 Results of the double-blind phase III study of more than 3,000 patients with high-risk, HER2-negative breast cancer showed no improvement in invasive...
Expert Point of View: Martin Reck, MD, PhD
The discussant of the PEARLS/KEYNOTE-091 trial, Martin Reck, MD, PhD, underscored the need to do more in the perioperative management of patients with early-stage non–small cell lung cancer (NSCLC) to improve rates of overall survival and relapse after surgery. Dr. Reck is Head of the Department of ...
Study Reports Adjuvant Pembrolizumab Improves Disease-Free Survival in Early-Stage NSCLC
Adjuvant pembrolizumab improves disease-free survival compared with placebo in patients with early-stage non–small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy when indicated. These findings from the PEARLS/KEYNOTE-091 trial were reported in a European Society for ...
Expert Point of View: Amit M. Oza, MD, MBBS
The invited discussant of the phase III ENGOT-EN5/GOG-3055/SIENDO trial was Amit M. Oza, MD, MBBS, Head of the Division of Medical Oncology & Hematology at University Health Network/Mount Sinai, Director of Clinical Research and Clinical Cancer Research Unit at Princess Margaret Hospital, and ...
Selinexor Improves Progression-Free Survival in Endometrial Cancer
In the treatment of advanced endometrial cancer, maintenance therapy with oral selinexor after response to first-line chemotherapy may result in a significantly reduced risk of disease progression, according to the results of the global phase III ENGOT-EN5/GOG-3055/SIENDO trial, presented at the...
Andrew Chapman, DO, FACP, Appointed Director of the Sidney Kimmel Cancer Center–Jefferson Health, Philadelphia
Andrew Chapman, DO, FACP, has been named Director of the Sidney Kimmel Cancer Center–Jefferson Health, with locations in Philadelphia and nearby areas in Pennsylvania and New Jersey. He has also been named the Center’s Executive Vice President for Oncology Services. He has served as the Center’s...
Fox Chase Cancer Center Appoints Elizabeth Plimack, MD, MS, as Deputy Director
Elizabeth Plimack, MD, MS, has been appointed to Deputy Director at Fox Chase Cancer Center in Philadelphia, according to Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase. Dr. Plimack is Chief of the Division of Genitourinary Medical Oncology and Professor in the Department of...
Selinexor in Previously Treated Advanced Dedifferentiated Liposarcoma
In the phase II/III SEAL trial reported in the the Journal of Clinical Oncology, Gounder et al found that selinexor significantly improved progression-free survival and time to subsequent treatment in previously treated advanced dedifferentiated liposarcoma, with the greatest benefit observed in...
